tirzepatide for psoriasis Lilly's Zepbound and Taltz improve symptoms, drive weight loss in study Eli Lilly Trial Shows Superior

When evaluating tirzepatide's safety profile, it is helpful to contextualize cancer risk relative to other diabetes and obesity medications

The appetite-suppressing properties of Mounjaro are dose-dependent, typically becoming more pronounced as the dosage is gradually increased according to the prescribing schedule in the Summary of Product Characteristics (SmPC)

Get a real plan before you lose the wrong kind of weight

ABSI showed only a correlation trend with HDL-c ( = -0.278, p = 0.070) ( Supplementary Table 2 )

Glucagon-like peptide-1 receptor agonists have demonstrated significant weight loss and cardiovascular benefits in both patients with and without diabetes, including a reduction in major adverse cardiovascular events